1. Home
  2. INCY vs LKQ Comparison

INCY vs LKQ Comparison

Compare INCY & LKQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • LKQ
  • Stock Information
  • Founded
  • INCY 1991
  • LKQ 1998
  • Country
  • INCY United States
  • LKQ United States
  • Employees
  • INCY N/A
  • LKQ N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • LKQ Motor Vehicles
  • Sector
  • INCY Health Care
  • LKQ Consumer Discretionary
  • Exchange
  • INCY Nasdaq
  • LKQ Nasdaq
  • Market Cap
  • INCY 13.4B
  • LKQ 10.9B
  • IPO Year
  • INCY 1993
  • LKQ 2003
  • Fundamental
  • Price
  • INCY $58.21
  • LKQ $42.03
  • Analyst Decision
  • INCY Hold
  • LKQ Strong Buy
  • Analyst Count
  • INCY 20
  • LKQ 5
  • Target Price
  • INCY $74.00
  • LKQ $52.60
  • AVG Volume (30 Days)
  • INCY 2.3M
  • LKQ 2.9M
  • Earning Date
  • INCY 04-29-2025
  • LKQ 04-24-2025
  • Dividend Yield
  • INCY N/A
  • LKQ 2.86%
  • EPS Growth
  • INCY N/A
  • LKQ N/A
  • EPS
  • INCY 0.15
  • LKQ 2.62
  • Revenue
  • INCY $4,241,216,999.00
  • LKQ $14,355,000,000.00
  • Revenue This Year
  • INCY $12.21
  • LKQ $1.15
  • Revenue Next Year
  • INCY $9.20
  • LKQ $2.89
  • P/E Ratio
  • INCY $345.39
  • LKQ $16.06
  • Revenue Growth
  • INCY 14.76
  • LKQ 3.53
  • 52 Week Low
  • INCY $50.35
  • LKQ $35.56
  • 52 Week High
  • INCY $83.95
  • LKQ $49.50
  • Technical
  • Relative Strength Index (RSI)
  • INCY 40.69
  • LKQ 53.36
  • Support Level
  • INCY $57.05
  • LKQ $38.07
  • Resistance Level
  • INCY $59.95
  • LKQ $42.50
  • Average True Range (ATR)
  • INCY 2.76
  • LKQ 1.53
  • MACD
  • INCY 0.18
  • LKQ 0.01
  • Stochastic Oscillator
  • INCY 46.45
  • LKQ 73.33

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About LKQ LKQ Corporation

Since forming in 1998 to consolidate the auto salvage business in the United States, LKQ has developed into a leading distributor of aftermarket and recycled auto parts with around 1,500 facilities across North America and Europe. The company primarily sells into the professional channel and offers an assortment of collision and mechanical parts to both body shops and mechanical repair shops. It also continues to operate more than 70 LKQ pick-your-part junkyards. Separate from the self-service business, LKQ typically purchases around 250,000 salvage vehicles annually that are used to extract vehicle parts for resale.

Share on Social Networks: